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ABSTRACT  
Cytochrome P450 2A6 (CYP2A6) is the principal enzyme 
involved in the metabolic activation of tobacco-specific 
nitrosamines to their ultimate carcinogenic forms and metabolism 
of nicotine. The present study was developed to investigate the 
genetic polymorphism of CYP2A6 in Javanese Indonesian subjects 
carrying the CYP2A6*1 allele and the CYP2A6*4. The whole gene 
deletion of CYP2A6 (CYP2A6*4) may inhibit smokers from giving 
up smoking, but appears to function as a protective factor 
against some cancer. However, the investigation of these         
allele,  a major functional polymorphisms common in Asian 
populations, have not been reported among Javanese Indonesian 
population. A single polymerase chain reaction-restriction 
fragment length polymorphism was used to resolve the 
genotypes into CYP2A6*1 (wild type) and CYP2A6*4 
(CYP2A6del). The sample studied consisted of 100 healthy 
subject that consist of 50 non smokers and 50 smoker from 
Javanese Indonesian population. The allele frequencies of *1 
(wild type) and *4, were 47.5 and 52.5%, respectively. When the 
two allel were considered simultaneously, among the non-
smokers, 45% were genotyped for CYP2A6*1/*4 and 5% were 
genotyped for CYP2A6*4/*4; on the other hand all of the smoker 
were genotyped for CYP2A6*1/*4 and there was no homozygote 
of wild type. Based on the data collected, it could be concluded 
that the polymorphism of CYP2A6 were detected in among 
Javanese population sample study and the allele frequencies of 
CYP2A6*4 were high.  
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INTRODUCTION 
The cytochrome P450 2A6 (CYP2A6) 
gene is expressed at a high level in liver and at 
lower levels in nasal mucosa and respiratory 
tract (Fernandez-Salguero et al., 1995). CYP2A6 
plays an important role in the activation of 
many procarcinogens, including aflatoxin B1, 
N-nitrosodiethylamine, and 1,3-butadiene and 
some tobacco-related nitrosamines, as well as in 
the clearance of some pharmaceuticals 
(Kushida et al., 2000; Oscarson, 2001; Raunio et 
al., 2008; Yoshida et al., 2002). In addition, 
CYP2A6 is involved in the metabolism of 
nicotine, the primary compound in tobacco 
that establishes and maintains tobacco 
dependence (Benowitz et al., 2011; Gullstén, 
2000; Hukkanen et al., 2005; Messina et al., 
1997; Oscarson, 2001). 
A genetic polymorphism of CYP2A6 
was recognized as one of the causes for the 
interindividual differences in the metabolism of 
nicotine (Heravi et al., 2010; Johnstone et al., 
2006; Kwon et al., 2001; Lea et al., 2005; 
Nagano et al., 2010; Nakajima et al., 2006; Yang 
et al., 2001). There are 80 numbered CYP2A6 
allelic variants identified to date, however, not 
all have been functionally characterized 
(www.cypalleles.ki.se/cyp2a6.htm). Among 80 
CYP2A6 allelic variants, CYP2A6*4 presents a 
whole gene deletion (Oscarson et al., 1999), that 
accounts for the majority of poor metabolizer 
(PM) in Asian populations (Nakajima and 
Yokoi, 2005; Oscarson, 2001).   
The CYP2A6*4 allele is of great 
importance in correlation studies, for example, 
smoking behaviour,  pre-carcinogen   activation  
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or drug metabolism to the CYP2A6 genotype, 
in particular when oriental populations are 
investigated (Oscarson, 2001). Subjects who are 
homozygotes for CYP2A6*4 are completely 
deficient in nicotine formation and 
polymorphism may inhibit smokers from giving 
up smoking (Ando et al., 2003; Ariyoshi et al., 
2002; Fujieda et al., 2004; Minematsu et al., 
2006; Rao et al., 2000). However, since the 
subjects lacking the CYP2A6 gene cannot 
activate N-nitrosamines such as NNK and N′-
nitrosonornicotine, which are contained in 
tobacco smoke as nicotine-derived carcinogens, 
it indicates that smokers carrying the 
CYP2A6*4 allele might have less risk of 
tobacco-related cancers (Ariyoshi et al., 2002; 
Fujieda et al., 2004; Liu et al., 2013; Minematsu 
et al., 2003; Nowell et al., 2002; Topcu et al., 
2002; Wang et al., 2013). 
A high frequency of CYP2A6*4 among 
Malaysian Malay population was reported 
(Yusof and Gan, 2009), but in Indonesian 
population the allele frequency of CYP2A6*4 
have not been reported yet. The present study 
was developed to investigate the genetic 
polymorphism of CYP2A6 in Javanese 
Indonesian subjects carrying the CYP2A6*1 
allele and the CYP2A6*4.  
 
MATERIAL AND METHODS 
Subjects and data collection 
Individuals involved in this study had to 
have Javanese parents and grandparents. 
Subjects were healthy male volunteers, between 
18 and 50 years-old, took no concurrent 
medications, and had no illnesses requiring 
investigation or treatment and have signed a 
statement of informed consent. This study was 
approved by the Ethics Committees of Medical 
Research Gadjah Mada University (Yogyakarta, 
Indonesia). 
The sample population involved 100 
adult subjects (50 non smokers and 50 
smokers) that were recruited from students and 
staffs of Sanata Dharma University. The non 
smokers were those who had never smoked in 
their life. Smokers were considered current 
smokers if they smoked up to 1 year before the 
date of the interview, not currently planning to 
stop smoking, smoke between 1 and 30 
cigarettes daily. Information was collected on 
the amount of cigarettes smoked per day 
(CPD), the age at which the subject started 
smoking, the nicotine content of the cigarettes, 
and time to smoke the first cigarette of the day, 
which is generally accepted as a clinical index 
for nicotine dependence (Kubota et al., 2006). 
 
CYP2A6 genotyping 
Blood samples were collected from 
venous blood samples into EDTA containing 
tubes and genomic DNA was extracted by the 
salting-out method using Ron's Blood and Cell 
DNA Mini Kit (Bioron-GmbH). The 
genotyping of CYP2A6*4 was based on 
polymerase chain reaction (PCR)/restriction 
fragment length polymorphism and was 
performed by a previously described method 
(Ariyoshi et al., 2000; Muroi et al., 2012) with 
minor modifications. Briefly, a novel forward 
primer named 2A6-B6 (5’-CCT CAT CAC 
ACA CAA CTT CCT C-3’) and a reverse 
primer named 2A6-UTRAS1 (5’-TGT AAA 
ATG GGC ATG AAC GCC C-3’) were used 
to amplify the common regions of CYP2A6*1 
and CYP2A6*4. The PCR reaction was 
perform using KAPA HiFi HotStart PCR Kit 
(Kapa Biosystems) that contained 1 x Kapa GC 
Rich HiFi Buffer (contain 2mM MgCl2), 0.3mM 
Kapa dNTP Mix, 0.3μM 2A6-B6, 0.3μM 2A6-
UTRAS1, 1 U Kapa HiFi HotStart DNA 
Polymerase, and approximately 50ng of 
genomic DNA in a final volume of 25μL. PCR 
was carried out under the following conditions: 
initial denaturation at 95°C for 5min; followed 
by 30 cycles of denaturation at 98°C for 20s, 
annealing at 64°C for 15s and extension at 
72°C for 30s; and subsequently a final 
extension at 72°C for 5min. The PCR product 
patterns were analyzed by electrophoresis with 
1% agarose gel. The PCR products consisted of 
1358-bp fragments from the CYP2A6*1 allele 
and 1356-bp fragments from the CYP2A6*4 
allele; these fragments were digested with 
Eco81 I (Thermo Scientific). The digestion 
patterns were analyzed by electrophoresis with 
1% agarose gel. Fragments of 824 bp and 728 
bp were derived from the CYP2A6*1 and 
CYP2A6*4 alleles, respectively.  
 
Data analysis 
Two CYP2A6 alleles (CYP2A6*1 (wild 
type allele), and CYP2A6*4 were identified           
in the Javanese Indonesian subjects used              
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in the study. According to the genotypes, 
subjects were divided into three groups:       
normal metabolizers, low metabolizers              
and poor metabolizers. In brief, normal                         
metabolizers were defined as having allele *1/*1; 
slow metabolizers had allele *1/*4 which was 
associated with 50% of the activity of normal 
metabolizers; and poor metabolizers had allele 
*4/*4 which was associated with less than 25% 
of the activity of normal metabolizers 
(Mwenifumbo et al., 2008; Schoedel et al., 2004). 
The frequencies of CYP2A6 genotypes for each 
allele were assessed using Hardy Weinberg 
distribution. Differences in allele frequencies 
and genotype among smokers and non smokers 
were assessed using the chi-square test. 
 
RESULT AND DISCUSSION 
The population heterogenity in 
Indonesia consists of ethnic classifications, 
based on continental origin, racial background 
or physical appearance. The main aim of the 
study was to investigate the distribution of 
cytochrome P450 2A6 (CYP2A6) among 
Javanese Indonesian people.  Two CYP2A6 
alleles (CYP2A6*1 (wild type allele) and 
CYP2A6*4  were identified in the Javanese 
subjects used in the study. The selection of 
variant alleles for genotyping was based on 
functional importance and occurance frequency 
in Asian (Nakajima and Yokoi, 2005; Oscarson, 
2001).  
We examined the frequency of the 
variant alleles in Javanese Indonesian that 
consist of 50 smokers and 50 nonsmoker with a 
mean age of 33 years (Table I). The smokers 
were selected according to their smoking habits 
which were categorized into three levels: light 
smokers (CPD: 1-10), intermediate smokers 
(CPD: 11-20) and heavy smokers (CPD: 21-30) 
(Yang et al., 2001). According to B-Rao (2001), 
the minimum sample size in genetic 
polymorphism studies with two allele detected 
is 50. In these sample size both alleles will be 
detected in high probability. 
In this study, the amplification of the 
CYP2A6*1 and CYP2A6*4 alleles were 
successfully carried out using polymerase chain 
reaction (PCR)/restriction fragment length 
polymorphism (Muroi et al., 2012). The primers 
2A6-B6 were used to amplify exon 8 (Nunoya 
et al., 1999) and the primers 2A6-UTRAS1 were 
used to amplify regions from exon 1 to the 3’-
untranslated region of the CYP2A6 gene. In 
this reaction, primers were specifically designed 
for amplification of either the CYP2A6*1 or 
the CYP2A6*4 allele, allowing for the 
convenient detection of heterozygous or 
homozygous carriers of the CYP2A6*4 allele. 
The CYP2A6*4 allele genotyped in this study 
was the  CYP2A6*4A variant, which is identical 
to CYP2A6*4C (Ariyoshi et al., 2000; Muroi et 
al., 2012). The CYP2A6*4C allele is suggested 
to have arisen due to an unequal crossing-over 
event with CYP2A7 (Nunoya et al., 1999). 
Studies on the CYP2A6 gene have been rather 
problematic, because the highly (94%) 
homologous CYP2A7 gene is located just 25kb 
upstream of the CYP2A6 gene (Rautio, 2003). 
In vitro DNA amplification of the 
CYP2A6 gene using these specific primers 
resulted in a 1358-bp fragments from the 
CYP2A6*1 allele and 1356-bp fragments from 
the CYP2A6*4 allele. Further, to differentiate 
between CYP2A6*1 allele and CYP2A6*4 
allele, the PCR products were digested using 
Eco801 I. The 824 bp and 728 bp were derived 
from the CYP2A6*1 and CYP2A6*4 alleles, 
respectively (Ariyoshi et al., 2000; Muroi et al., 
2012) (Figure 1). 
A PCR product was detected in all 
(100%) samples. Among 50 non smokers, 45% 
were genotype for CYP2A6*1/*4 and 5% were 
genotype for CYP2A6*4/*4; on the other hand 
all of the smoker were genotype for 
CYP2A6*1/*4.  These data suggested that the 
distribution of CYP2A6*1/*4 genotype 
frequency was not different significantly 
(χ2=3.841; P=0.022) between smokers and non 
smokers in this study population (Table II).  
The allele frequencies of CYP2A6*4 are 
highly variable among races.  The  reported  
frequencies  of  CYP2A6*4  allele   is  0.5%  in  
Spaniards (n=100), 15.1% in Chinese (n=96) 
(Oscarson et al., 1999), 1,2% in Caucasian 
(n=296)  (Rao et  al.,  2000),  11%  in  Korean  
(Kwon et  al.,  2001),  20.1%  in Japanese  
(n=92)  (Nakajima et  al.,  2001),  and  16.7%  in  
Malaysians  (n=24) (Yusof  and  Gan,  2009).  
Among  these  studies,  Asian  showed  to   
have a relatively  high  frequency  of  
CYP2A6*4  allele.  In  this  study,  the  allele 
frequencies  of  CYP2A6*1,  and  CYP2A6*4  
in  the  Javanese  Indonesian (n=100)  were   
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47.5%  and  52.5%,  respectively.  A  high  
frequencies  of CYP2A6*4  in  the  Javanese  
were  consistent  with  the  finding of  the  
other results above. 
In these study, no CYP2A6*1 
homozygous were found both in non smokers 
and smokers,  these data imply that there is no 
difference in the frequency of CYP2A6*4 
alleles among smokers when compared with 
non-smokers. It is worth noting that the gene 
deletion mutation CYP2A6*4 as being 
homozygous, was detected in only five out of 
the 50 non smokers tested.  
CYP2A6 deletion alleles (CYP2A6*4) are 
of great importance in studies to aimed at 
correlating smoking behaviour, pre-carcinogen 
activation or drug metabolism with the 
CYP2A6 genotype, especially in Oriental 
populations. A number of studies have found 
that smokers who inherit CYP2A6 alleles 
associated with slower nicotine metabolism 
presumably need to smoke fewer cigarettes to 
achieve the same pharmacological effect 
experienced by smokers who inherit CYP2A6 
alleles associated with faster nicotine 
metabolism. The study by Ariyoshi et al. (2002) 
exhibits a tendency of the subjects with the 
CYP2A6*1B/*1B genotype to smoke a higher 
number of cigarettes per day (average number 
20–40 cigarettes) than the subjects with the 
CYP2A6*1A/*1A genotype (average 20–30 
cigarettes). Ando et al. (2003) found the  lack of  
a  significant impact of  heterozygous CYP2A6  
deletion  on  smoking  behavior. Fujieda et al. 
(2004) reported that subjects carrying 
CYP2A6*4, CYP2A6*7, CYP2A6*9 and 
CYP2A6*10 alleles smoked significantly less 
than subjects with the CYP2A6*1/*1 genotype 
(combining CYP2A6*1A and CYP2A6*1B).  
Slow metabolizers smoked fewer cigarettes per 
day and had an earlier age of first smoking 
(Schoedel et al., 2004). According to Minematsu 
et al. (2006), homozygous mutants and 
compound heterozygotes  (CYP2A6*4, 
CYP2A6*7 and CYP2A6*9) smoked fewer 
cigarettes daily than heterozygotes and 
homozygous wild-type individuals 
(CYP2A6*1). CYP2A6 poor metabolizer 
genotypes were associated with lighter smoking, 
a later age of initiation and a shorter duration 
of smoking (Liu et al., 2011). However, these 
observations remain conflicting. Other studies 
have failed to detect an association between 
genetically low CYP2A6 activity and the 
number of cigarettes smoked. Genetic variation 
in CYP2A6 did not correlate with the ability to 
quit smoking (Kwon et al., 2001) and there is no 
significant difference in the smoking status was 
observed according to the CYP2A6 genotype 
(Gambier et al., 2005; Tan et al., 2001).  This  
discrepancy  may be partly  explained  by  the  
different  frequencies  of inactive allele.  
Regarding the basis for the classification 
of the CYP2A6 genotypes into three             
groups, we recently analyzed that all of                 
the smoker were classified as slow metabolizers           
as having CYP2A6*1/*4 genotype 
(Mwenifumbo et al., 2008; Schoedel et al., 2004). 
The  results indicate that the CYP2A6 genotype 
does not have any notable effect on the 
number  of    smoked cigarettes among     smokers.  
Table I. Demographic characteristics and CYP2A6 genotypes of subjects according to smoking 
status 
 
Characteristics  
Smoking status  
Non smokers 
Smokers  
Light Intermediete  Heavy 
Number of subjects  50 20 17 13 
Age     
Mean ± SD 
Range 
33±8 
18–45  
33.6±9.1 
18–45 
34.94±9.56 
18–46 
36.07±8.78 
22–47  
Number of CPD      
Mean ± SD 
Range 
– 8.15±1.17 
6–10 
13.06±1.03 
12–14 
22.69±0.95 
21–24 
 
Christine Patramurti 
Volume 26 Issue 1 (2015) 15 
Futhermore we did not find any significant 
association between CYP2A6 gene defect and 
tendency to tobacco smoker among Javanese 
participants. These observations are consistent 
with previous findings that impaired function 
of CYP2A6 could not reduce cigarette 
consumption. The similar frequency of the 
CYP2A6*4 genotype in non smokers and  
smokers may be important (Table II) in 
understanding the essential role of CYP2A6 
genotypes in smoking related diseases, because 
the CYP2A6*4 allele does not protect subjects 
from becoming habitual smokers. It is clear 
that CYP2A6 genetic variations are only part of 
the genetic basis of addiction to nicotine, 
smoking depends on many genetic and 
situational factors. 
CYP2A6 plays a major role in the 
metabolism of nicotine and coumarin, and  
involveds in the clearance of certain 
pharmaceuticals and the activation of some 
tobacco-related nitrosamines (Oscarson et al., 
1998; Pelkonen et al., 1999; Raunio et al.,          
2001). It is important to know whether the           
different alleles are producing active enzyme 
able to metabolize drugs and other toxic or 
carcinogenic chemicals. Daigo et al. (2002) 
found that when giving tegafur (an anticancer 
drug) to gastric cancer patients with a CYP2A6 
poor metabolizer status, the patient could not 
produce high enough concentrations of the 
active metabolite to have a beneficial effect of 
the drug treatment.  It is possible that in the 
future, when physicians prescribe medication to 
 
 
Figure 1. Electrophoregrame PCR product and Digested product identification of CYP2A6*1 and 
CYP2A6*4 allele. M1: Marker DNA Ladder, A: Isolated DNA, B: PCR Product (1358/1356bp), C: 
Digested Product (728bp) and D: Digested Product (824bp and 728bp), M2: Marker DNA ladder. 
 
Table II. CYP2A6 genotype and allele frequencies in the Javanese Indonesian according to 
smoking status 
 
Genotypes 
Observed Frequency  
Total 
Number of Subject (n=100) 
Nonsmoker 
(50) 
Smoker (50) 
Light  Intermediate Heavy 
CYP2A6*1/CYP2A6*1 
CYP2A6*1/CYP2A6*4 
CYP2A6*4/CYP2A6*4 
0 (0) 
45.0% (45) 
5.0% (5) 
0 (0) 
20.0% (20) 
0.0% (0) 
0 (0) 
17.0% (17) 
0.0% (0)  
0 (0) 
13.0% (13) 
0.0% (0) 
0 (0) 
95.0% (95) 
5.0% (5) 
Allele Number of Allele (n=200)   
CYP2A6*1 
CYP2A6*4 
 22.5% (45) 
 27.5% (55) 
10.0% (20) 
10.0% (20) 
8.5% (17%) 
8.5% (17%) 
6.5% (13) 
6.5% (13) 
47.5% (95) 
52.5% (105) 
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their patients, they need information on the 
patient’s CYP status. Other studies reported 
that the frequency of the CYP2A6*4C was 
significantly lower in the lung cancer patients 
than healthy volunteers, suggesting that the 
subjects carrying the CYP2A6*4C alleles are 
resistant to carcinogenesis caused by N-
nitrosamines because of the poor metabolic 
activation capacity (Islam et al., 2013; Kamataki 
et al., 2002; Muroi et al., 2012; Tan et al., 2001; 
Wang et al., 2013). It could be speculated that 
individuals who have CYP2A6*4 allele may also 
be less efficient at bioactivating tobacco smoke 
procarcinogens to carcinogens. 
 
CONCLUSION 
Based on the data collected, it could be 
concluded that the polymorphism of CYP2A6 
were detected in among Javanese population 
sample study and the allele frequencies of 
CYP2A6*4 were high. The findings of this 
study also provide evidence that among these 
sample study are more likely to be genetically 
slower nicotine metabolizers. However, to 
evaluate the real effect of CYP2A6 gene defect 
on addiction to tobacco smoke, further studies 
that more precisely address smoking addictive 
behavior, tobacco consumption and current 
smoke intake via measurement of valid 
biomarkers such as CO-hemoglobin, cotinine 
and 3-hydroxycotinine/cotinine ratio are 
necessary. 
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